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Abstract Central nervous system hemangioblastomas
occur sporadically and in patients with von Hippel–Lindau
(VHL) disease due to a VHL germline mutation. This
mutation leads to enhanced transcription of chemokine
receptor 4 (CXCR4), its ligand (CXCL12) and vascular
endothelial growth factor A (VEGFA). We aimed to
determine in VHL-related and sporadic hemangioblas-
tomas CXCR4, CXCL12, and VEGFA protein expression
and to correlate this to hemangioblastoma size and
expression in normal surrounding tissue. 27 patients with a
hemangioblastoma were included for analysis of
immunohistochemistry of tissue, MRI and DNA. Heman-
gioblastomas overexpress CXCR4, CXCL12, and VEGFA
compared to normal surrounding tissue. In sporadic
hemangioblastomas the mean percentage of CXCR4
positive hemangioblastoma cells was 16 %, SD 8.4, in
VHL-related hemangioblastomas 8 %, SD 4.4
(P = 0.002). There was no relation between preoperative
tumor size and CXCR4 or CXCL12 expression. Compared
to normal surrounding tissue CXCR4, CXCL12, and
VEGFA were overexpressed in hemangioblastomas. Most
interestingly, sporadic hemangioblastomas overexpress
CXCR4 compared to VHL-related hemangioblastoma.
Keywords CXCR4  CXCL12  Hemangioblastomas 
VEGF  VHL
Introduction
von Hippel–Lindau (VHL) disease is an autosomal domi-
nant syndrome leading to the onset of multi-organ benign
and malignant neoplasms including hemangioblastomas.
Hemangioblastomas are highly vascularized lesions com-
prising 1.1–2.4 % of central nervous system (CNS) neo-
plasms. Their principal components are hemangioblastoma
stromal cells with a low mitotic index and capillaries
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formed by normal endothelial cells with activated pericyte
coverage. Approximately a third of hemangioblastomas is
related to VHL-disease [1]. However, this might be an
underestimation as not all cases are screened for germ-line
VHL-mutations.
The characteristic vascularized appearance of heman-
gioblastomas in VHL-disease patients is thought to be
caused by the VHL-mutation leading to defective or absent
VHL protein (pVHL). Improper functioning pVHL fails to
degrade hypoxia inducible factor 1A (HIF1A) thereby
resulting in increased transcription of proteins such as
platelet-derived growth factor, transforming growth factor
A and vascular endothelial growth factor (VEGFA) [2–4].
Upon expression VEGFA is released into the environment
by the tumor cells and binds to its corresponding receptors
mainly on endothelial cells. In this way VEGFA primarily
induces endothelial cell proliferation and migration, pro-
moting the aberrant angiogenesis that supports tumor
growth and tumor metastasis [5].
Several in vitro and in vivo models have revealed a key
role of chemokine receptor 4 (CXCR4) and its ligand
CXCL12 in the crosstalking between cancer cells and their
microenvironment [6, 7]. CXCR4 is downregulated by the
VHL protein and upregulated by HIF1A. CXCR4 and
CXCL12 are co-expressed in CNS hemangioblastoma and
in renal clear cell carcinoma [8]. Large tumors have more
risk on hypoxic conditions. Increased hypoxia leads to
higher CXCR4 expression via HIF1a. Loss-of-function of
the VHL gene is responsible for the upregulation of the
expression of CXCR4, its ligand CXLC12, and VEGFA.
This is particularly interesting as these micro-environ-
mental factors are increasingly recognized and established
as novel drug targets [9].
Therefore, the aim of this study was to investigate
CXCR4, CXCL12, and VEGFA protein expression in
VHL-related and sporadic hemangioblastomas and to cor-
relate this to size as measured by MRI before surgery to
investigate possible differences between VHL-related and
sporadic hemangioblastoma. In order to verify the contri-
bution of somatic VHL mutations and hypermethylation of
hemangioblastomas we analyzed VHL mutations and pro-
moter methylation in the tumor tissue.
Materials and methods
Patients
All patients that were operated between 1995 and 2010 in
the University Medical Center Groningen from who frozen
hemangioblastoma tissue was available in the tissue bank
of the Department of Pathology were eligible. Patients
without a known germline mutation were classified as
having sporadic hemangioblastoma and patient with a
known germline mutation were as having VHL-related
hemangioblastoma. All patients apart from one, who
refused screening for germline VHL-mutation, were rou-
tinely tested for mutations.
Hemangioblastoma tissues were numerically tagged
according to a national coding system. Clinical data
obtained from VHL surveillance were used to retrieve data
on gender and age. Lesion size of both solid nodule and
associated cyst size were based on pre-operative MRI scan
and on written surgery reports. According to the VHL
guidelines, MRI scans from the cerebellum and myelum
were performed biennially [10–13], annually when a lesion
was present, and every 6 months when a lesion was found
to have increased in size until stable disease was ascer-
tained (www.stoet.nl, VHL working group). The largest
diameter in mm was used and surface area in mm2 was then
calculated. Solid tumor size was defined by the diameter of
only the solid nodule and cyst size by only the cystic part.
Total size was defined by largest diameter of both solid and
cystic part together. All data was stored in a computerized
anonymous database. Patient identity was protected by
unique codes. The Medical Ethical Review Board declared
that based on Dutch law no further approval for use of
residual tissue for analysis, including DNA analysis, was
needed.
Immunohistochemistry
Cryosections (4 lm) were morphologically defined as
hemangioblastoma by hematoxylin and eosin (H&E)
staining. For CXCR4, CXCL12, and VEGFA staining, the
fixation procedure was followed by endogenous peroxidase
blockage by 1 % (w/v) hydrogen peroxidase. CXCR4 was
stained in dilution 1:500 (polyclonal rabbit #ab2074,
Abcam, Cambridge, UK) and CXCL12 in dilution 1:60
(monoclonal mouse #MAB350, R&D Systems, Abingdon,
UK). VEGFA staining was performed using the avidin–
biotin complex method (avidin–biotin blocking kit, Vector
Laboratories, Peterborough, UK) with anti-VEGFA as
primary antibody in dilution 1:50 (polyclonal rabbit #sc-
152, Santa Cruz, Heidelberg, Germany). All secondary and
tertiary goat anti rabbit horse radish peroxidase (HRP),
rabbit anti goat HRP and rabbit anti mouse HRP, secondary
swine anti rabbit biotinylated antibodies and streptavidin-
HRP were obtained from Dako (Glostrup, Denmark).
Frozen sections of glioblastoma (WHO grade 4) served as
positive controls for CXCR4 and VEGFA. Cytospins of
renal cell carcinoma cells (RCC786, authenticated by STR
analysis) served as the positive controls for CXCL12. For
negative controls, the primary antibodies were omitted.
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Normal surrounding brain tissue, small fragments of
preexistent normal brain parenchyma excised during
debulking surgery, was verified by morphology on H&E
staining. CXCR4 quantitative evaluation was performed by
counting the percentage of positive cells (of total cells) in 5
random, but qualitatively good, high power fields (4009
magnification) per hemangioblastoma slide. CXCL12 semi
quantitative evaluation was performed in 5 high power
fields (4009 magnification) per slide and defined as neg-
ative, positive ([1 % positive cells) or strongly positive
([50 % positive cells or high intensity). VEGFA was
evaluated by describing morphology of tissue (normal
brain tissue, vascular endothelium and stromal heman-
gioblastoma cells) in relation to positive cells. Evaluation
and quantification was performed by two independent
observers (RCK and NK) blinded to the diagnosis, using
NDP software (Hamamatsu, Almere, the Netherlands) after
scanning slides with a Hamamatsu scanner (Hamamatsu).
DNA isolation
For DNA isolation frozen hemangioblastoma scrapings (10
times 10 lm) were collected from all 33 hemangioblas-
tomas. Also 2 male and 2 female samples of normal tissue
were collected. DNA was extracted using dissolving buffer
[4 mol/l guanidine thiocyanate-buffer, DNase free water,
96 % ethanol and further digested in Tris EDTA (TE)-
buffer (10 mmol/l Tris/HCl, pH = 7.5, 1 mmol/l EDTA
with proteinase K and sodium dodecyl sulfate 10 % (w/
v))]. Standard salt extraction and isopropanol precipitation
was used for high molecular DNA and dissolved in 150 ll
TE-buffer. For quality control, genomic DNA was ampli-
fied in a multiplex PCR according to the BIOMED-2
protocol [14].
Sequencing and multiplex ligation-dependent probe
amplification (MLPA)
Germline mutations were defined by inherited mutations in
VHL or inherited loss of the whole gene as found in loss of
heterozygosity (LOH) analysis. Exons 1, 2 and 3 of VHL
and their flanking sequences were amplified by PCR. PCR
products were purified and subjected to sequence analysis
using an ABI 3730 automated DNA sequencer (Applied
Biosystems, Life Technologies Corporation, CA, USA). To
detect genomic deletions involving single or multiple
exons of VHL, an MLPA-assay (MRC-Holland SALSA
MLPA P016 VHL probe mix, Amsterdam, the Nether-
lands) was performed according to the manufacturer’s
instructions. For the interpretation of sequence alterations,
the Alamut (Interactive Biosoftware, Rouen, France)
decision-support software package was used.
Methylation specific PCR (MSP)
MSP was performed after bisulphite treatment on dena-
tured genomic DNA. Bisulphite treatment was performed
with the EZ DNA methylation kit according the manu-
facturer’s protocol (Zymogen, BaseClear, Leiden, the
Netherlands). For PCR 15 ng of bisulphite treated DNA
was used. The b-actin gene served as an internal reference.
Primer pair sequences are listed in Supplementary Table 2
(designed with Methyl Primer Express v1.0, Invitrogen).
PCR products were visualized on a 2.5 % (w/v) agarose
gel. A sample was considered positive (methylated or
hypermethylated) when a PCR product of the right size was
visible after 40 cycles of PCR. Leukocyte DNA collected
from anonymous healthy volunteers and in vitro CpG
methylated DNA with SssI (CpG) methyltransferase (New
England Biolabs Inc., Beverly, MA, USA) were used as
negative and positive control, respectively.
Statistical analysis
Statistical analysis was done using Kruskal–Wallis test,
linear regression and Spearman rank correlation. P values
of\0.05 were considered significant.
Results
Thirty-three specimens of 27 patients operated between
1995 and 2010 for central nervous system hemangioblas-
toma were analyzed. Sixteen specimens were from 11
VHL-disease patients (seven with 1, three with 2 and one
patient with 3 specimens) and 17 specimens from 16 spo-
radic cases (15 with 1 and one with 2 specimens) (Table 1).
In 27 specimens sufficient DNA was available to per-
form mutation analysis (Table 2, Supplementary Table 1).
In 76.9 % of cases (10 out of 13) of VHL-related heman-
gioblastomas only the germline mutation was found, in
15.4 % (2 out of 13) two mutations were present (second
hit) and in one case 3 mutations were found. In the sporadic
hemangioblastomas, 57 % (8 out of 14) were mutated. In
two out of 27 hemangioblastomas specimens the VHL
promoter was hypermethylated, both were sporadic
hemangioblastoma cases (Fig. 1).
CXCR4, CXCL12 and VEGFA expression
All hemangioblastoma cells, excluding endothelial cells,
showed CXCR4 expression (n = 29, as 4 slides were not
evaluable; Fig. 2A). In the 16 sporadic hemangioblastomas
the mean percentage of CXCR4 positive cells per specimen
(16 %, range 1–38 %) was higher as compared to the 13
VHL-related hemangioblastomas (8 %, range 3–19 %,
Difference in CXCR4 expression between sporadic and VHL-related hemangioblastoma 609
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Age at time of surgery
in years (range)
Sex
Male 21 (64 %) 17 47 (13–62)
Female 12 (36 %) 10 41 (14–65)
VHL-mutation carriers 16 (48 %) 11 (41 %) 46 (26–65)
c.259_260-insA p.Val87Aspfs*45 1 (6 %)
c.-89-?_c297??del. p(?) 7 (44 %)
c.341-59_341-14del p.? 1 (6 %)
c.462A[C p.Pro154Pro 1 (6 %)
c.500G[A p.Arg167Gln 3 (19 %)
c.463?2T[C p.(?) 1 (6 %)
c.490C[T p.Gln164* 2 (13 %)
Sporadic 17 (52 %) 16 (59 %) 44 (13–62)
Table 2 Occurrence of VHL-mutations and CXCR4 expression in the hemangioblastoma (HB) specimens









Two normal alleles – – 43 (6/14) 17.0
One mutation 76.9 (10/13) 8.2 14.3 (2/14) 16.5
Two mutations 15.4 (2/13) 10.2 7.1 (1/14) 16.1
LOH 0 – 21.4 (3/14) 24.5
One mutation and LOH 0 – 14.3 (2/14) 12.1
Three mutations 7.7 (1/13) 7.3 0 –
Fig. 1 All VHL methylation specific PCR (MSP) products, 33
hemangioblastoma tissues (numbered 1–17 sporadic cases, 18–33
VHL related cases) and controls (in vitro CpG methylated DNA with
Sssl CpG methyltransferase (IV), leukocyte and water), on agarose
gel. From each sample the first lane is the methylated DNA and the
second lane the unmethylated DNA. Hemangioblastoma derived
DNA sample 7 and 15 (boxes) show methylation of the VHL-
promoter, both these samples were derived from sporadic heman-
gioblastoma patients. Experiments were performed in triplicate
610 R. C. Kruizinga et al.
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P = 0.002; Fig. 2b; Table 2). In the 15 available normal
surrounding brain tissue samples no CXCR4 expression
was observed.
Thirty two samples were evaluable for CXCL12
expression. Sporadic and VHL-related hemangioblastomas
had the same level of CXCL12 expression (Fig. 2c), with
strong expression in 75 % (12 out of 16) of sporadic
hemangioblastomas and in 81 % (13 out of 16) of VHL-
related hemangioblastoma cells. The normal tissue showed
no (n = 12) or in a few cases (n = 3) some expression of
CXCL12 (Fig. 3). VEGFA was expressed higher than
normal in sporadic and VHL-related hemangioblastomas,
and present in stromal hemangioblastoma cells and vas-
cular endothelial cells (Fig. 4).
Correlation between CXCR4 expression and clinical
variables
Sporadic hemangioblastomas and associated cyst size did
not differ from VHL-related hemangioblastomas (sporadic:
median solid tumor size 547.5 mm2, median total size
1316.3 mm2 and VHL-related: median solid tumor size
235.75 mm2, and median total size 545.88 mm2, P = 0.09
for both; Fig. 5).
The tumor and associated cyst size was not correlated to
the CXCR4 expression level (95 % confidence interval
298.8; 700.1 mm2 rho = 0.39, P = 0.069 for tumor nodule
and 95 % confidence interval 763.7; 1295.5 mm2
rho = 0.095, P = 0.644 for total size; Fig. 5).
Discussion
This study shows that CXCR4, CXCL12, and VEGFA are
all overexpressed in stromal hemangioblastoma cells
compared to normal surrounding brain tissue. This is the
first study in which expression of CXCR4, CXCL12, and
VEGFA is compared in both sporadic and VHL associated
hemangioblastoma patients. Earlier studies in VHL related
hemangioblastoma found upregulated CXCR4, CXCL12,
and VEGFA. In contrast, studies in VHL-related renal cell
carcinoma and retinal hemangioblastoma high levels of
Fig. 2 a Representative pictures CXCR4 immunohistochemistry
(940 magnification) on sporadic (left) and VHL-disease related
(right) hemangioblastoma specimens. CXCR4 expression is present in
all hemangioblastoma cells, excluding endothelial cells [vessels are
depicted by an asterisk (*)]. b, c Box plots of percentage of CXCR4
positive cells (b) and CXCL12 staining intensity (c) per field of view
in sporadic and VHL-disease related hemangioblastoma specimens
showing a higher mean percentage of CXCR4 positive cells but
similar CXCL12 expression in sporadic hemangioblastoma compared
to VHL-related hemangioblastoma. Linear regression, *P\ 0.05.
The bars represent the range
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CXCR4 and VEGF, and not CXCL12, were found [15–17].
In the current study CXCL12 and VEGFA expression was
similar in sporadic and VHL-related cases.
The finding that CXCR4 expression was higher in spo-
radic hemangioblastomas is striking as in VHL-disease a
germline mutation in VHL leads to a defect VHL protein
which results in enhanced transcription of CXCR4, its
ligand CXCL12 as well as VEGFA [8]. To analyze the
possible reason for the observed difference we determined
the genetic background of hemangioblastomas of both
VHL-related and sporadic cases. The onset of lesion for-
mation in VHL-disease occurs when the inherited germline
mutation is accompanied by a second hit, e.g. a mutation in
the normal allele. Previous studies reported inactivation of
both alleles of VHL in 62 of VHL-disease related heman-
gioblastoma [20]. For VHL-related renal cell carcinoma
this percentage is even higher, 86.6 % [21]. In sporadic
hemangioblastomas VHL is inactivated as well. Others
reported that in 20–50 % of cases one allele was inacti-
vated and in 0–13 % both VHL alleles [20, 22–27]. Our
Fig. 3 Hemangioblastoma tissue overexpresses CXCL12 compared
to normal tissue as depicted in the representative pictures of CXCL12
immunohistochemistry on VHL-disease (a 940 magnification and
b computer magnification) and hemangioblastoma (c 940 magnifi-
cation and d computer magnification) specimens [normal tissue
within hemangioblastoma specimen depicted by an asterisk (*)]
Fig. 4 Stromal hemangioblastoma cells and vascular endothelial cells show higher immunohistochemical (940 magnification) VEGFA
expression in sporadic (left) and VHL-related (right) than normal tissue in hemangioblastoma specimens
612 R. C. Kruizinga et al.
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data show that in all VHL-related and in the majority of
sporadic hemangioblastomas a mutation, LOH or hyper-
methylation of the VHL was present. In addition no dif-
ference in CXCR4 expression between patients with and
without a VHL-mutation was found and thus could not
explain the observed difference in CXCR4 expression in
VHL and sporadic hemangioblastomas.
Next we hypothesized that the size of hemangioblas-
tomas at the time of surgery might explain the observed
difference in CXCR4 expression and analyzed MRIs for
hemangioblastoma size. Bulky tumors develop more
hypoxia then smaller ones. Therefore, bulky tumors, with
more hypoxia, are hypothesized to express higher levels of
CXCR4, as hypoxia and CXCR4 upregulation are corre-
lated [15]. Hypoxia has been found to be inversely corre-
lated to tumor size in murine models [18, 19]. Although
VHL patients are screened by biennial MRI [10–13] we did
not find a significant difference in preoperative size of
VHL-related and sporadic hemangioblastomas and associ-
ated cysts.
We also determined the genetic background of heman-
gioblastomas of both VHL-related and sporadic cases. The
onset of lesion formation in VHL-disease occurs when the
inherited germline mutation is accompanied by a second
hit, e.g. a mutation in the normal allele. Previous studies
reported inactivation of both alleles of VHL in 62 of VHL-
disease related hemangioblastoma [20]. For VHL-related
renal cell carcinoma this percentage is even higher, 86.6 %
[21]. In sporadic hemangioblastomas VHL is inactivated as
well. Others reported that in 20–50 % of cases one allele was
inactivated and in 0–13 % both VHL alleles [20, 22–27]. Our
data show that in all VHL-related and in the majority of
sporadic hemangioblastomas a mutation, LOH or hyperme-
thylation of the VHL was present. In addition no difference in
CXCR4 expression between patients with and without a VHL-
mutation was found and thus could not explain the observed
difference in CXCR4 expression in VHL and sporadic
hemangioblastomas.
We and others found CXCR4 overexpressed in heman-
gioblastoma cells compared to normal surrounding brain
tissue [8]. The difference in CXCR4 expression between
these two cell types might be caused by their difference in
origin, the hemangioblastoma cell is a mesoderm-derived,
embryologically arrested hemangioblast [22]. As the
CXCR4 expression is limited to hemangioblastoma tissue,
this potentially creates opportunities for treatment with
drugs specifically targeting CXCR4 expressing cells. Since
CXCR4 expression is involved in primary tumor growth
[28], tumor invasiveness [29], metastasis [29], angiogene-
sis [30] and vasculogenesis [31], this subpopulation of
CXCR4 overexpressing cells can be targeted by CXCR4
inhibitors. The tumor growth-stimulating role of CXCR4
Fig. 5 a Boxplots of size in mm2 of solid tumor (left), cyst (middle)
and largest total diameter (right) of the sporadic and VHL-disease
related hemangioblastoma specimens, measured on pre-operative
MRI images (bars represent the range). Hemangioblastomas and
associated cyst size was similar for sporadic and VHL-related
hemangioblastoma specimens. b Solid tumor (left), cyst (middle) and
total (right) hemangioblastoma size in mm2 and the percentage of
CXCR4 positive cells per field of view measured by CXCR4
immunohistochemistry were not correlated
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was confirmed by showing that CXCR4 antagonists inhibit
tumor growth in multiple experimental orthotopic, subcu-
taneous human xenograft, and transgenic mouse models
[32]. In a transgenic breast cancer mouse model, treatment
with the CXCR4 inhibition CTCE-9908 resulted in a 56 %
reduction in primary tumor growth rate compared to con-
trols receiving scrambled protein. Moreover, this coincided
with a 42 % reduction in vascular endothelial growth factor
(VEGF) protein expression and 30 % reduction in p-AKT/
AKT expression [32]. Furthermore, in various cancer
models metastasis of cancer cells was revealed to be
mediated by CXCR4 activation and directed migration
towards CXCL12 expressing organs [33–37]. Experimental
metastatic mouse models have provided evidence that
targeting CXCR4 impairs cancer cell metastasis [29, 32,
37–42]. The CXCR4 inhibitor AMD3100 is FDA approved
for use in patients with non-Hodgkin’s lymphoma and
multiple myeloma. It is registered to be used as stem cell
mobilizer [43] and is tested as investigational agent as
anticancer drug for other cancers [44].
For VHL-related hemangioblastoma, targeted therapy
against CXCR4 and VEGFA could potentially be com-
bined with conventional therapy as VHL-related disease is
multiple and lesions often reoccur after surgery [45–47].
Besides, as VHL disease is an autosomal dominant multi-
system neoplastic syndrome [48, 49] targeted therapy
would be a good option to treat VHL disease at other sites,
for example (metastasizing) renal cell carcinoma. We also
found VEGFA overexpressed in stromal hemangioblas-
toma cells as compared to normal surrounding brain tissue.
Bevacizumab, an anti-VEGFA monoclonal antibody, has
been extensively investigated in several settings, ranging
from single agent treatment to combined modality
approaches in both recurrent and newly diagnosed malig-
nancies [50]. Preclinical experiments show that the com-
bination of AMD3100 and bevacizumab may help prevent
the growth of certain tumors like gliomas [51, 52]. In the
presence of HIF1a bone marrow-derived CD45 ? myeloid
cells containing Tie2?, VEGFR1?, CD11b?, and F4/80?
subpopulations, as well as endothelial and pericyte pro-
genitor cells promote neovascularization, party trough
increase in CXCL12, the ligand of CXCR4. MMP-9
activity of bone marrow-derived CD45? cells is essential
to initiate angiogenesis by increasing VEGF bioavailability
[51]. Impaired pVHL fails to degrade HIF1a resulting in
increased VEGFA levels and therefore combined CXCR4
and VEGFA inhibition could be of potential benefit for
VHL patients. A phase I study of the CXCR4 inhibitor
plerixafor and bevacizumab is ongoing for patients with
recurrent high-grade gliomas (NCT01339039). This com-
bination could be potentially of high interest for both VHL
related and sporadic patients with hemangioblastoma.
Conclusions
CXCR4, CXCL12, and VEGFA were all overexpressed in
hemangioblastomas as compared to normal surrounding tissue.
Sporadic hemangioblastomas express more CXCR4 as com-
pared to VHL-related hemangioblastoma. The difference in
CXCR4 expression was not explained by size, orVHLmutation
and/or hypermethylation. CXCR4 expression in heman-
gioblastoma tissue potentially creates treatment opportunities
with drugs specifically targeting CXCR4 expressing cells.
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